HBsAg, Anti-HBs, Anti-HCV and Anti-HIV seroprevalence of the patients applied to Bitlis State Hospital and Tatvan State Hospital

Amaç: Günümüzde viral hepatitler ve HIV enfeksiyonu önemli sağlık sorunlarıdır. Bu çalışmanın amacı 1 Aralık 2012 ve 30 Kasım 2013 tarihleri arasında Bitlis Devlet Hastanesi ve Tatvan Devlet Hastanesine başvuran bireylerde; HBsAg, anti-HBs, anti-HCV ve anti-HIV seropozitiflik oranlarının belirlenmesidir. Gereç ve Yöntem: Hastalardan alınan kan örnekleri CMIA (Chemiluminescent Microparticle İmmunoassay) yöntemi ile çalışılmıştır. Bulgular: HBsAg için 20.484 serum örneği incelendi ve bu örneklerin 933’ünde (% 4,5) HBsAg pozitifdi. Anti-HBs için 16.695 serum örneği incelendi ve bu örneklerin 5.759’unda (% 34,4) anti-HBs pozitifdi. Anti-HCV için 19.685 serum örneği incelendi ve bu örneklerin 8’inde (% 0,09) anti-HCV pozitifdi, Anti-HIV için 14.874 serum örneği incelendi ve bu örneklerin 1’inde (% 0,007) anti-HIV pozitifdi. Sonuç: Sonuç olarak, viral hepatitler ilimiz için önemli sağlık problemleridir. Bölgemizdeki HBsAg seropozitifliği ülkemiz oranlarıyla uyumlu olup, anti-HIV ve anti-HCV pozitifliği Türkiye ortalamasının altında çıkmıştır.Objective: At the present time viral hepatitis and HIV infection are important health problems. The aim of this study was to investigate the rates of HBsAg, anti-HBs, anti-HCV and anti-HIV seropositivity in people those admitted to Bitlis State Hospital and Tatvan State Hospital between December 2012 and November 2013. Material and Methods: Blood samples from the patients were analysed in using chemiluminescence method. Results: For HBsAg, 20.484 samples were analyzed and 933 (4,5 %) of these samples were positive. For anti-HBs, 16.965 samples were analyzed and 5.759 (34,4 %) of these samples were positive. For antiHCV 19.685 samples were analyzed and 18 (0,09 %) of these samples were positive. For anti-HIV 14874 samples were analyzed and only 1 sample was positive (0,007 %). Conclusion: In conclusion; despite the relatively lower rate of HIV seropositivity, hepatitis viruses, particularly HBV remains to be a significant health problem in our province. The seropositivity rates for HBsAg in our region were comparable to those seen across Turkey. Whereas, the seropositivity rates for anti-HIV and anti-HCV were lower than the average rate in Turkey

HBsAg, Anti-HBs, Anti-HCV and Anti-HIV seroprevalence of the patients applied to Bitlis State Hospital and Tatvan State Hospital

Amaç: Günümüzde viral hepatitler ve HIV enfeksiyonu önemli sağlık sorunlarıdır. Bu çalışmanın amacı 1 Aralık 2012 ve 30 Kasım 2013 tarihleri arasında Bitlis Devlet Hastanesi ve Tatvan Devlet Hastanesine başvuran bireylerde; HBsAg, anti-HBs, anti-HCV ve anti-HIV seropozitiflik oranlarının belirlenmesidir. Gereç ve Yöntem: Hastalardan alınan kan örnekleri CMIA (Chemiluminescent Microparticle İmmunoassay) yöntemi ile çalışılmıştır. Bulgular: HBsAg için 20.484 serum örneği incelendi ve bu örneklerin 933’ünde (% 4,5) HBsAg pozitifdi. Anti-HBs için 16.695 serum örneği incelendi ve bu örneklerin 5.759’unda (% 34,4) anti-HBs pozitifdi. Anti-HCV için 19.685 serum örneği incelendi ve bu örneklerin 8’inde (% 0,09) anti-HCV pozitifdi, Anti-HIV için 14.874 serum örneği incelendi ve bu örneklerin 1’inde (% 0,007) anti-HIV pozitifdi. Sonuç: Sonuç olarak, viral hepatitler ilimiz için önemli sağlık problemleridir. Bölgemizdeki HBsAg seropozitifliği ülkemiz oranlarıyla uyumlu olup, anti-HIV ve anti-HCV pozitifliği Türkiye ortalamasının altında çıkmıştır.Objective: At the present time viral hepatitis and HIV infection are important health problems. The aim of this study was to investigate the rates of HBsAg, anti-HBs, anti-HCV and anti-HIV seropositivity in people those admitted to Bitlis State Hospital and Tatvan State Hospital between December 2012 and November 2013. Material and Methods: Blood samples from the patients were analysed in using chemiluminescence method. Results: For HBsAg, 20.484 samples were analyzed and 933 (4,5 %) of these samples were positive. For anti-HBs, 16.965 samples were analyzed and 5.759 (34,4 %) of these samples were positive. For antiHCV 19.685 samples were analyzed and 18 (0,09 %) of these samples were positive. For anti-HIV 14874 samples were analyzed and only 1 sample was positive (0,007 %). Conclusion: In conclusion; despite the relatively lower rate of HIV seropositivity, hepatitis viruses, particularly HBV remains to be a significant health problem in our province. The seropositivity rates for HBsAg in our region were comparable to those seen across Turkey. Whereas, the seropositivity rates for anti-HIV and anti-HCV were lower than the average rate in Turkey

Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity

Background/Aims: Tumor necrosis factor-? (TNF-?) inhibitors and ustekunimab are widely used in autoimmune diseases. It is known that these biological agents cause the reactivation of hepatitis B virus (HBV). There is no standardized strategy to prevent the reactiva- tion in patients with evidence of a previous HBV infection. In our study, anti-HBc IgG-positive patients who received a biological agent were evaluated in terms of HBV reactivation. Materials and Methods: Patients who were followed up for the use of biological agents in our clinic were evaluated retrospectively. Pa- tients with isolated anti-HBc IgG positivity were included in the study. The HBV reactivation data were recorded from the patients’ files retrospectively. Results: Two hundred and seventy-eight patients who received biological treatment were evaluated. Twenty-nine patients with isolated anti-HBc IgG positivity or resolved HBV infection were included in the study. The HBV reactivation was seen in 5 patients (17.2%). Of these patients, 3 were using adalimumab, 1 infliximab, and 1 ustekunimab. It was controlled by antiviral therapy that was started in the early period. Conclusion: Drugs that block TNF-? and ustekunimab cause an increase in viral replication. In literature, the HBV reactivation rate was approximately 1% in HBsAg-negative, anti-HBC IgG-positive cases, whereas it was found to be as high as 17.2% in our study. Patients receiving the immunomodulator therapy should be evaluated for HBV serology before treatment and carefully monitored for HBV reac- tivation during and after treatment